Please login to the form below
Urovant
This page shows the latest Urovant news and features for those working in and with pharma, biotech and healthcare.
Sumitomo Dainippon goes big on biotech with $3bn Roivant deal
The five companies Sumitomo is set to take over from Roivant include Myovant, Urovant, Enzyvant, Altavant and another undisclosed spinout company. ... Although Sumitomo will gain a major stake in Urovant and Myovant (75% and 45%), the Japanese pharma
Latest news
-
Urovant slips on phase 3 incontinence drug data
Underwhelming results send shares down. Vivek Ramaswamy’s Roivant group hasn’t been able to chalk up many clinical successes, and a phase 3 win for its Urovant unit in urinary ... If approved, it would become the first new prescription drug in nearly
-
Daily Brief: setback for Akcea/Ionis, Urovant adds gene therapy, Metrion gains funding
Urovant Sciences has licensed a novel gene therapy for patients with overactive bladder (OAB) symptoms who have failed oral pharmacologic therapy. ... Urovant is part of the Roivant group of companies, which has been investing heavily in new gene therapy
-
Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use
Urovant prepares for IPO. Urovant Sciences is to make its debut on the Nasdaq exchange, looking to raise $150m from an IPO. ... Urovant aims to investigate the drug’s use in overactive bladder (OAB), as well as another trial in OAB patients with benign
-
Roivant gets $1.1bn investment from Japan's SoftBank
Roivant - the holding company for subsidiaries Axovant, Myovant, Dermavant, Enzyvant and just-launched urology specialist Urovant - said the cash injection will be used to launch new subsidiaries "within and beyond the ... Urovant, launched in June, is
More from news
Approximately 1 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Onyx Health
Hart Biologicals. Health Tech Enterprise. Lexicon Pharmaceuticals. Nova Laboratories. Polyphotonix. Urovant Sciences.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
- Associate Director - Global Healthcare Consulting
- £100,000 - £115,000 yearly
- Early Access Program - Regulatory Affairs (EAP-RA)
- Highly competitive salary
-
Pharmacovigilance Project Lead
- Highly competitive salary
-
Pharmacovigilance Manager
- Highly competitive salary
-
Senior Medical Writer
- Highly competitive salary
- Strategy Director - Healthcare Advertising
- £90,000 - £120,000 yearly
-
Technical Sales Representative
- Highly competitive salary
-
Omnichannel Account Director
- £55,000 - £65,000 yearly
- FDA proposes improvements for oncology clinical trials supporting accelerated approval
- AbbVie’s Parkinson’s disease therapy application rejected by FDA
- AstraZeneca’s mild combination asthma reliever approved in UK
- Eli Lilly increases investment to almost $1bn for new Irish manufacturing facility
- Merck reports positive results for Keytruda plus chemotherapy in endometrial cancer
- AstraZeneca/MSD’s Lynparza combination approved in UK for prostate cancer
- Bristol Myers Squibb’s Sotyktu approved by EC for plaque psoriasis
- Positive results for Almirall’s lebrikizumab in atopic dermatitis published in NEJM and BJD
- When to call in the specialists: strategy in Medical Affairs
- Time to talk about health inequalities
- Powering Rapid Cognitive Analysis with AI
- AstraZeneca and Amgen’s Tezspire recommended by NICE for severe asthma
PMHub
Oncosec
OncoSec is a clinical-stage biotechnology company focused on developing cytokine-based intratumoral immunotherapies to stimulate the body's immune system to target...
Latest intelligence
- Time to talk about health inequalities
- Health inequalities are increasingly being recognised as a crucial healthcare challenge in the UK...
- The speed of science and the pace of comms
- Pharma red tape slows comms but there is a solution, Paul Hutchings, founder of fox&cat, writes....
- Improving cardiovascular disease care and awareness
- Scott Curley talks to PME about the risks of CVD and the importance of getting the right treatment at the right time...
